Signaling through ShcA is required for transforming growth factor β- and Neu/ErbB-2-induced breast cancer cell motility and invasion

Molecular and Cellular Biology

Volumn 28, Issue 10, 2008, Pages 3162-3176

  Northey, Jason J ^a   Chmielecki, Juliann ^a   Ngan, Elaine ^a   Russo, Caterina ^a   Annis, Matthew G ^a   Muller, William J ^a   Siegel, Peter M ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN SHC; TRANSFORMING GROWTH FACTOR BETA; TYROSINE;

ANIMAL CELL; ARTICLE; AUTOPHOSPHORYLATION; BREAST CANCER; BREAST TUMOR; CANCER CELL; CARBOXY TERMINAL SEQUENCE; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CELL MOVEMENT; FEMALE; FOCAL ADHESIONS; GENE EXPRESSION; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; PHOSPHOTYROSINE; POINT MUTATION; RECEPTOR, ERBB-2; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 43249109660     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.01734-07     Document Type: Article

References (73)

1. Andrulis, I. L., S. B. Bull, M. E. Blackstein, D. Sutherland, C. Mak, S. Sidlofsky, K. P. Pritzker, R. W. Hartwick, W. Hanna, L. Lickley, R. Wilkinson, A. Qizilbash, U. Ambus, M. Lipa, H. Weizel, A. Katz, M. Baida, S. Mariz, G. Stoik, P. Dacamara, D. Strongitharm, W. Geddie, D. McCready, et al. 1998. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. J. Clin. Oncol. 16:1340-1349.
2. Bakin, A. V., C. Rinehart, A. K. Tomlinson, and C. L. Arteaga. 2002. p38 mitogen-activated protein kinase is required for TGFβ-mediated fibroblastic transdifferentiation and cell migration. J. Cell Sci. 115:3193-3206.
3. Bakin, A. V., A. K. Tomlinson, N. A. Bhowmick, H. L. Moses, and C. L. Arteaga. 2000. Phosphatidylinositol 3-kinase function is required for transforming growth factor β-mediated epithelial to mesenchymal transition and cell migration. J. Biol. Chem. 275:36803-36810.
4. Balaban, N. Q., U. S. Schwarz, D. Riveline, P. Goichberg, G. Tzur, I. Sabanay, D. Mahalu, S. Safran, A. Bershadsky, L. Addadi, and B. Geiger. 2001. Force and focal adhesion assembly: a close relationship studied using elastic micropatterned substrates. Nat. Cell Biol. 3:466-472.
5. Bargmann, C. I., M. C. Hung, and R. A. Weinberg. 1986. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 45:649-657.
6. Bargmann, C. I., and R. A. Weinberg. 1988. Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion. EMBO J. 7:2043-2052.
7. Beningo, K. A., M. Dembo, I. Kaverina, J. V. Small, and Y. L. Wang. 2001. Nascent focal adhesions are responsible for the generation of strong propulsive forces in migrating fibroblasts. J. Cell Biol. 153:881-888.
8. Bhowmick, N. A., M. Ghiassi, A. Bakin, M. Aakre, C. A. Lundquist, M. E. Engel, C. L. Arteaga, and H. L. Moses. 2001. Transforming growth factor-β1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol. Biol. Cell 12:27-36.
9. Bierie, B., and H. L. Moses. 2006. Tumour microenvironment: TGFβ: the molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer 6:506-520.
10. Bouchard, L., L. Lamarre, P. J. Tremblay, and P. Jolicoeur. 1989. Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell 57:931-936.
11. Carragher, N. O., and M. C. Frame. 2004. Focal adhesion and actin dynamics: a place where kinases and proteases meet to promote invasion. Trends Cell Biol. 14:241-249.
12. Coll, J. L., A. Ben-Ze'ev, R. M. Ezzell, J. L. Rodriguez Fernandez, H. Baribault, R. G. Oshima, and E. D. Adamson. 1995. Targeted disruption of vinculin genes in F9 and embryonic stem cells changes cell morphology, adhesion, and locomotion. Proc. Natl. Acad. Sci. USA 92:9161-9165.
13. Collins, L. R., W. A. Ricketts, L. Yeh, and D. Cheresh. 1999. Bifurcation of cell migratory and proliferative signaling by the adaptor protein Shc. J. Cell Biol. 147:1561-1568.
14. Dankort, D., N. Jeyabalan, N. Jones, D. J. Dumont, and W. J. Muller. 2001. Multiple ErbB-2/Neu phosphorylation sites mediate transformation through distinct effector proteins. J. Biol. Chem. 276:38921-38928.
15. Dankort, D., B. Maslikowski, N. Warner, N. Kanno, H. Kim, Z. Wang, M. F. Moran, R. G. Oshima, R. D. Cardiff, and W. J. Muller. 2001. Grb2 and Shc adapter proteins play distinct roles in Neu (ErbB-2)-induced mammary tumorigenesis: implications for human breast cancer. Mol. Cell. Biol. 21:1540-1551.
16. Dankort, D. L., Z. Wang, V. Blackmore, M. F. Moran, and W. J. Muller. 1997. Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation. Mol. Cell. Biol. 17:5410-5425.
17. Di Fiore, P. P., O. Segatto, F. Lonardo, F. Fazioli, J. H. Pierce, and S. A. Aaronson. 1990. The carboxy-terminal domains of erbB-2 and epidermal growth factor receptor exert different regulatory effects on intrinsic receptor tyrosine kinase function and transforming activity. Mol. Cell. Biol. 10:2749-2756.
18. Friedman, D. B., S. E. Wang, C. W. Whitwell, R. M. Caprioli, and C. L. Arteaga. 2007. Multivariable difference gel electrophoresis and mass spectrometry: a case study on transforming growth factor-β and ERBB2 signaling. Mol. Cell. Proteomics 6:150-169.
19. Gallant, N. D., K. E. Michael, and A. J. Garcia. 2005. Cell adhesion strengthening: contributions of adhesive area, integrin binding, and focal adhesion assembly. Mol. Biol. Cell 16:4329-4340.
20. Gotoh, N., M. Toyoda, and M. Shibuya. 1997. Tyrosine phosphorylation sites at amino acids 239 and 240 of Shc are involved in epidermal growth factor-induced mitogenic signaling that is distinct from Ras/mitogen-activated protein kinase activation. Mol. Cell. Biol. 17:1824-1831.
21. Guy, C. T., R. D. Cardiff, and W. J. Muller. 1992. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol. Cell. Biol. 12:954-961.
22. Guy, C. T., M. A. Webster, M. Schaller, T. J. Parsons, R. D. Cardiff, and W. J. Muller. 1992. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. USA 89:10578-10582.
23. Hazan, R., B. Margolis, M. Dombalagian, A. Ullrich, A. Zilberstein, and J. Schlessinger. 1990. Identification of autophosphorylation sites of HER2/neu. Cell Growth Differ. 1:3-7.
24. Holbro, T., R. R. Beerli, F. Maurer, M. Koziczak, C. F. Barbas III, and N. E. Hynes. 2003. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl. Acad. Sci. USA 100:8933-8938.
25. Huber, M. A., N. Kraut, and H. Beug. 2005. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr. Opin. Cell Biol. 17:548-558.
26. Hudis, C. A. 2007. Trastuzumab - mechanism of action and use in clinical practice. N. Engl. J. Med. 357:39-51.
27. Jones, R. B., A. Gordus, J. A. Krall, and G. MacBeath. 2006. A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature 439:168-174.
28. Khoury, H., D. L. Dankort, S. Sadekova, M. A. Naujokas, W. J. Muller, and M. Park. 2001. Distinct tyrosine autophosphorylation sites mediate induction of epithelial mesenchymal like transition by an activated ErbB-2/Neu receptor. Oncogene 20:788-799.
29. Lehnert, D., B. Wehrle-Haller, C. David, U. Weiland, C. Ballestrem, B. A. Imhof, and M. Bastmeyer. 2004. Cell behaviour on micropatterned substrata: limits of extracellular matrix geometry for spreading and adhesion. J. Cell Sci. 117:41-52.
30. Marmor, M. D., K. B. Skaria, and Y. Yarden. 2004. Signal transduction and oncogenesis by ErbB/HER receptors. Int. J. Radiat. Oncol. Biol. Phys. 58:903-913.
31. Marone, R., D. Hess, D. Dankort, W. J. Muller, N. E. Hynes, and A. Badache. 2004. Memo mediates ErbB2-driven cell motility. Nat. Cell Biol. 6:515-522.
32. Mehra, A., and J. L. Wrana. 2002. TGF-β and the Smad signal transduction pathway. Biochem. Cell Biol. 80:605-622.
33. Miettinen, P. J., R. Ebner, A. R. Lopez, and R. Derynck. 1994. TGF-β-induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J. Cell Biol. 127:2021-2036.
34. Moustakas, A., and C. H. Heldin. 2005. Non-Smad TGF-β signals. J. Cell Sci. 118:3573-3584.
35. Muller, W. J., E. Sinn, P. K. Pattengale, R. Wallace, and P. Leder. 1988. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54:105-115.
36. Muraoka, R. S., Y. Koh, L. R. Roebuck, M. E. Sanders, D. Brantley-Sieders, A. E. Gorska, H. L. Moses, and C. L. Arteaga. 2003. Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor β1. Mol. Cell. Biol. 23:8691-8703.
37. Muraoka-Cook, R. S., I. Shin, J. Y. Yi, E. Easterly, M. H. Barcellos-Hoff, J. M. Yingling, R. Zent, and C. L. Arteaga. 2006. Activated type I TGFβ receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression. Oncogene 25:3408-3423.
38. Owens, R. B., H. S. Smith, and A. J. Hackett. 1974. Epithelial cell cultures from normal glandular tissue of mice. J. Natl. Cancer Inst. 53:261-269.
39. Perou, C. M., T. Sorlie, M. B. Eisen, M. van de Rijn, S. S. Jeffrey, C. A. Rees, J. R. Pollack, D. T. Ross, H. Johnsen, L. A. Akslen, O. Fluge, A. Pergamenschikov, C. Williams, S. X. Zhu, P. E. Lonning, A. L. Borresen-Dale, P. O. Brown, and D. Botstein. 2000. Molecular portraits of human breast tumours. Nature 406:747-752.
40. Rauh, M. J., V. Blackmore, E. R. Andrechek, C. G. Tortorice, R. Daly, V. K. Lai, T. Pawson, R. D. Cardiff, P. M. Siegel, and W. J. Muller. 1999. Accelerated mammary tumor development in mutant polyomavirus middle T transgenic mice expressing elevated levels of either the Shc or Grb2 adapter protein. Mol. Cell. Biol. 19:8169-8179.
41. Rodrigues, S. P., K. E. Fathers, G. Chan, D. Zuo, F. Halwani, S. Meterissian, and M. Park. 2005. CrkI and CrkII function as key signaling integrators for migration and invasion of cancer cells. Mol. Cancer Res. 3:183-194.
42. Rodríguez Fernández, J. L., B. Geiger, D. Salomon, and A. Ben-Ze'ev. 1992. Overexpression of vinculin suppresses cell motility in BALB/c 3T3 cells. Cell Motil. Cytoskeleton 22:127-134.
43. Romond, E. H., E. A. Perez, J. Bryant, V. J. Suman, C. E. Geyer, Jr., N. E. Davidson, E. Tan-Chiu, S. Martino, S. Paik, P. A. Kaufman, S. M. Swain, T. M. Pisansky, L. Fehrenbacher, L. A. Kutteh, V. G. Vogel, D. W. Visscher, G. Yothers, R. B. Jenkins, A. M. Brown, S. R. Dakhil, E. P. Mamounas, W. L. Lingle, P. M. Klein, J. N. Ingle, and N. Wolmark. 2005. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353:1673-1684.
44. Salcini, A. E., J. McGlade, G. Pelicci, I. Nicoletti, T. Pawson, and P. G. Pelicci. 1994. Formation of Shc-Grb2 complexes is necessary to induce neoplastic transformation by overexpression of Shc proteins. Oncogene 9:2827-2836.
45. Saunders, R. M., M. R. Holt, L. Jennings, D. H. Sutton, I. L. Barsukov, A. Bobkov, R. C. Liddington, E. A. Adamson, G. A. Dunn, and D. R. Critchley. 2006. Role of vinculin in regulating focal adhesion turnover. Eur. J. Cell Biol. 85:487-500.
46. Schade, B., S. H. Lam, D. Cernea, V. Sanguin-Gendreau, R. D. Cardiff, B. L. Jung, M. Hallett, and W. J. Muller. 2007. Distinct ErbB-2 coupled signaling pathways promote mammary tumors with unique pathologic and transcriptional profiles. Cancer Res. 67:7579-7588.
47. Schulze, W. X., L. Deng, and M. Mann. 2005. Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol. Syst. Biol. 1:2005.0032.
48. Seton-Rogers, S. E., Y. Lu, L. M. Hines, M. Koundinya, J. LaBaer, S. K. Muthuswamy, and J. S. Brugge. 2004. Cooperation of the ErbB2 receptor and transforming growth factor β in induction of migration and invasion in mammary epithelial cells. Proc. Natl. Acad. Sci. USA 101:1257-1262.
49. Shi, Y., and J. Massague. 2003. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 113:685-700.
50. Siegel, P. M., D. L. Dankort, W. R. Hardy, and W. J. Muller. 1994. Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol. Cell. Biol. 14:7068-7077.
51. Siegel, P. M., and J. Massague. 2003. Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nat. Rev. Cancer 3:807-821.
52. Siegel, P. M., E. D. Ryan, R. D. Cardiff, and W. J. Muller. 1999. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J. 18:2149-2164.
53. Siegel, P. M., W. Shu, R. D. Cardiff, W. J. Muller, and J. Massague. 2003. Transforming growth factor β signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc. Natl. Acad. Sci. USA 100:8430-8435.
54. Slamon, D. J., G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, and W. L. McGuire. 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182.
55. Slamon, D. J., W. Godolphin, L. A. Jones, J. A. Holt, S. G. Wong, D. E. Keith, W. J. Levin, S. G. Stuart, J. Udove, A. Ullrich, et al. 1989. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712.
56. Slamon, D. J., B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming, W. Eiermann, J. Wolter, M. Pegram, J. Baselga, and L. Norton. 2001. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344:783-792.
57. Smith, M. J., W. R. Hardy, J. M. Murphy, N. Jones, and T. Pawson. 2006. Screening for PTB domain binding partners and ligand specificity using proteome-derived NPXY peptide arrays. Mol. Cell. Biol. 26:8461-8474.
58. Sørlie, T., C. M. Perou, R. Tibshirani, T. Aas, S. Geisler, H. Johnsen, T. Hastie, M. B. Eisen, M. van de Rijn, S. S. Jeffrey, T. Thorsen, H. Quist, J. C. Matese, P. O. Brown, D. Botstein, P. Eystein Lonning, and A. L. Borresen-Dale. 2001. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 98:10869-10874.
59. Sorlie, T., R. Tibshirani, J. Parker, T. Hastie, J. S. Marron, A. Nobel, S. Deng, H. Johnsen, R. Pesich, S. Geisler, J. Demeter, C. M. Perou, P. E. Lonning, P. O. Brown, A. L. Borresen-Dale, and D. Botstein. 2003. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. USA 100:8418-8423.
60. Sotiriou, C., S. Y. Neo, L. M. McShane, E. L. Korn, P. M. Long, A. Jazaeri, P. Martiat, S. B. Fox, A. L. Harris, and E. T. Liu. 2003. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl. Acad. Sci. USA 100:10393-10398.
61. Sotiriou, C., and M. J. Piccart. 2007. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat. Rev. Cancer 7:545-553.
62. Ueda, Y., S. Wang, N. Dumont, J. Y. Yi, Y. Koh, and C. L. Arteaga. 2004. Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor β-induced cell motility. J. Biol. Chem. 279:24505-24513.
63. Ursini-Siegel, J., B. Schade, R. D. Cardiff, and W. J. Muller. 2007. Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat. Rev. Cancer 7:389-397.
64. van der Geer, P., S. Wiley, G. D. Gish, and T. Pawson. 1996. The Shc adaptor protein is highly phosphorylated at conserved, twin tyrosine residues (Y239/240) that mediate protein-protein interactions. Curr. Biol. 6:1435-1444.
65. Wang, S. E., I. Shin, F. Y. Wu, D. B. Friedman, and C. L. Arteaga. 2006. HER2/Neu (ErbB2) signaling to Rac1-Pak1 is temporally and spatially modulated by transforming growth factor β. Cancer Res. 66:9591-9600.
66. Wang, S. E., F. Y. Wu, I. Shin, S. Qu, and C. L. Arteaga. 2005. Transforming growth factor β (TGF-β)-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-β function. Mol. Cell. Biol. 25:4703-4715.
67. Webster, M. A., J. N. Hutchinson, M. J. Rauh, S. K. Muthuswamy, M. Anton, C. G. Tortorice, R. D. Cardiff, F. L. Graham, J. A. Hassell, and W. J. Muller. 1998. Requirement for both Shc and phosphatidylinositol 3′ kinase signaling pathways in polyomavirus middle T-mediated mammary tumorigenesis. Mol. Cell. Biol. 18:2344-2359.
68. Xie, L., B. K. Law, M. E. Aakre, M. Edgerton, Y. Shyr, N. A. Bhowmick, and H. L. Moses. 2003. Transforming growth factor β-regulated gene expression in a mouse mammary gland epithelial cell line. Breast Cancer Res. 5:R187-R198.
69. Xu, W., H. Baribault, and E. D. Adamson. 1998. Vinculin knockout results in heart and brain defects during embryonic development. Development 125:327-337.
70. Xu, W., J. L. Coll, and E. D. Adamson. 1998. Rescue of the mutant phenotype by reexpression of full-length vinculin in null F9 cells; effects on cell locomotion by domain deleted vinculin. J. Cell Sci. 111:1535-1544.
71. Yang, Y. A., O. Dukhanina, B. Tang, M. Mamura, J. J. Letterio, J. MacGregor, S. C. Patel, S. Khozin, Z. Y. Liu, J. Green, M. R. Anver, G. Merlino, and L. M. Wakefield. 2002. Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects. J. Clin. Investig. 109:1607-1615.
72. Zaidel-Bar, R., M. Cohen, L. Addadi, and B. Geiger. 2004. Hierarchical assembly of cell-matrix adhesion complexes. Biochem. Soc. Trans. 32:416-420.
73. Ziegler, W. H., R. C. Liddington, and D. R. Critchley. 2006. The structure and regulation of vinculin. Trends Cell Biol. 16:453-460.